Zoetis announced the U.S. commercial launch of Solensia™ (Frunevetmab injection) as the first and only monoclonal antibody treatment to control osteoarthritis pain in cats approved in the U.S.

Complimentary Commercial Content

Zoetis has researched pain progression in cats and now knows that a protein known as Nerve Growth Factor is a key driver of OA pain. By targeting NGF, Solensia controls cats’ OA pain, helping them to regain their quality of life by increasing their mobility and improving their overall comfort.

Source: Zoetis, September 26, 2022. Link.  To learn more about Solensia, please visit www.SolensiaVetTeam.com.